ENG
Emphysema Market Industry Analysis and Forecast (2025-2032)
Emphysema Market size was valued at USD 4.91 Bn. in 2024 and the total Emphysema Market size is expected to grow at a CAGR of 4.28% from 2025 to 2032, reaching nearly USD 6.86 Bn. by 2032.
Format : PDF | Report ID : SMR_2066
Emphysema Market Overview
Emphysema is a lung illness within the lower respiratory system where the alveoli (lung air sacs) are impaired leading to less oxygen being moved into the bloodstream. Tobacco smoking, high levels of air pollution and exposure to chemical fumes and dust have been identified as the main drivers of the emphysema market as a result of increasing prevalence of respiratory infections. In addition, the market is also growing because of the rising incidences of genetic disorders caused by inherited gene mutations and DNA abnormalities. On another note, this is because there has been more over the years use of effective medications for example bronchodilators, corticosteroids or anti-inflammatory drugs in treating this condition.
Lung scintigraphy, help to detect the most severely affected parts of the lungs, is also acting as a significant growth-inducing factor, utilizing radioisotopes to visualize lung ventilation and perfusion. Targeted biologics such as monoclonal antibodies for targeting eosinophilic inflammation moreover are anticipated to encourage widespread adoption due to their efficacy in reducing disease exacerbation.
To get more Insights: Request Free Sample Report
Emphysema Market Dynamics
Drivers: Growing Aging Population
The elderly are greatly responsible for the large emphysema drug market. Emphysema is more common in old people due to continuous inhalation of dangerous substances like first and secondhand smoking. Within time, the need for such drugs in addition to treatment approaches will be on the increase, as global population gradually ages. This is very apparent especially in developed countries where people live long.
Advancements in Drug Delivery Systems
There have been significant advances in the pharmaceutical field with regards to improved drug delivery systems that target emphysema. For instance, devices like inhalers, nebulizers, among others have been developed so that people can receive different types of medicines for instance into the lung more easily. It is also true that such innovation promotes better adherence on the part of clients as they allow them to give themselves treatment without any help.
Restrain/Challenges
Increasing Cost of Treatment Therapeutics
Factors that contribute to the increase in the cost of treating emphysema include advanced therapeutic options, such as medications, pulmonary rehabilitation programs, and surgical interventions like lung volume reduction surgery or lung transplantation. In addition, treatment expenses are further increased by the management of co-morbidities that are associated with Emphysema.
Emphysema Market Segment Analysis:
Based on Type Emphysema Market is divided into Centriacinar, Panacinar, Paraseptal, and Others. The centriacinar segment dominated the global emphysema treatment market share in 2024 and is expected to register the fastest growth in the forecast period, owing to the fact that centriacinar is one of the most prevalent forms of emphysema, particularly among smokers, who represent a significant portion of the population affected by this condition. Centriacinar is characterized by damage primarily to the central or proximal portions of the acinus within the lungs. While Panacinar and Paraseptal are used in serious condition to give instant effect on patients.
Emphysema Market Regional Insights:
Region Wise North America Dominated the Emphysema Market. In the United States and Canada, emphysema is a significant public health concern due to high smoking rates and environmental factors. Advanced healthcare infrastructure and extensive research contribute to the availability of a wide range of treatment options, including pharmaceuticals, pulmonary rehabilitation programs, and surgical interventions. The market is characterized by the presence of key players offering innovative therapies and a strong emphasis on personalized medicine approaches. Moreover, the emphysema market is influenced by regional healthcare infrastructure, socio-economic factors, and environmental conditions, shaping the distribution and adoption of therapies worldwide.
North America Emphysema Market attributed to advanced medical facilities available in the region and high level of healthcare spending, which facilitates the adoption of novel treatments for emphysema. In addition, extensive R and D activities, along with a supportive regulatory environment, have propelled the development and commercialization of emphysema treatment products in North America.
Emphysema Market Competitive Landscape
- In December 2023, AstraZeneca India, a science-led biopharmaceutical company, announced that it has received Central Drugs Standard Control Organization (CDSCO) approval to market its inhalation aerosol, a triple combination of budesonide (160 mcg), glycopyrrolate (9 mcg), and formoterol fumarate (4.8 mcg) for maintenance treatment of COPD.
- In August 2023, clinical research was conducted on the biologic medication Dupixent which was developed by Regeneron and Sanofi in a collaboration. The trial showcased positive results indicating that it could be used to treat COPD exacerbations and improve lung function effectively. Dupixent is an approved drug and is used for treating patients with eczema or allergic asthma.
- In March 2022, the department of veteran’s affairs launched its novel HER in Columbus, Ohio at the VA Central Ohio healthcare system
Emphysema Market Scope
|
Emphysema Market |
|
|
Market Size in 2024 |
USD 4.91 Bn. |
|
Market Size in 2032 |
USD 6.86 Bn. |
|
CAGR (2025-2032) |
4.28 % |
|
Historic Data |
2019-2024 |
|
Base Year |
2024 |
|
Forecast Period |
2025-2032 |
|
Segments |
By Type
|
|
By Treatment
|
|
|
By Distribution Channel
|
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Emphysema Market Key Players
- GlaxoSmithKline plc. (UK)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Eli Lilly and Company. (U.S.)
- AstraZeneca (UK)
- Pfizer Inc. (U.S.)
- Takeda Pharmaceutical Company Limited. (Japan)
- Bristol-Myers Squibb Company (U.S.)
- Sanofi (France)
- Bayer AG (Germany)
- AbbVie Inc. (U.S.)
- Allergan (Ireland)
- Precigen (U.S.)
- Pulmonx Corporation (U.S.)
- Halozyme, Inc. (U.S.)
- Mmariposa Health (U.S.)
- Kamada Pharmaceuticals (Israel)
- Olympus Corporation (Japan)
- Spiration, Inc.(U.S.)
- Lifetech Scientific (China)
- XX Inc
Frequently Asked Questions
Adverse Effects and related diseases are the restrain of Emphysema Market.
Emphysema Market size was valued at USD 4.91 Billion in 2024 and the total Emphysema Market size is expected to grow at a CAGR of 4.28 % from 2025 to 2032, reaching nearly USD 6.86 Billion by 2032.
Segments are covered based on By Type, By Treatment, By Distribution Channel.
1. Research Methodology
1.1 Research Data
1.1.1. Primary Data
1.1.2. Secondary Data
1.2. Market Size Estimation
1.2.1. Bottom-Up Approach
1.2.2. Top-Down Approach
1.3. Market Breakdown and Data Triangulation
1.4. Research Assumption
2. Emphysema Market Executive Summary
2.1. Market Overview
2.2. Market Size (2024) and Forecast (2025 – 2032) and Y-O-Y%
2.3. Market Size (USD) and Market Share (%) – By Segments and Regions
3. Global Emphysema Market: Competitive Landscape
3.1. SMR Competition Matrix
3.2. Key Players Benchmarking
3.2.1. Company Name
3.2.2. Headquarter
3.2.3. Service Segment
3.2.4. End-user Segment
3.2.5. Y-O-Y%
3.2.6. Revenue (2024)
3.2.7. Profit Margin
3.2.8. Market Share
3.2.9. Company Locations
3.3. Market Structure
3.3.1. Market Leaders
3.3.2. Market Followers
3.3.3. Emerging Players
3.4. Consolidation of the Market
3.4.1. Strategic Initiatives and Developments
3.4.2. Mergers and Acquisitions
3.4.3. Collaborations and Partnerships
3.4.4. New Product/Service Launches and Innovations
4. Emphysema Market: Dynamics
4.1. Emphysema Market Trends by Region
4.1.1. North America
4.1.2. Europe
4.1.3. Asia Pacific
4.1.4. Middle East and Africa
4.1.5. South America
4.2. Emphysema Market Drivers
4.3. Emphysema Market Restraints
4.4. Emphysema Market Opportunities
4.5. Emphysema Market Challenges
4.6. PORTER’s Five Forces Analysis
4.6.1. Intensity of the Rivalry
4.6.2. Threat of New Entrants
4.6.3. Bargaining Power of Suppliers
4.6.4. Bargaining Power of Buyers
4.6.5. Threat of Substitutes
4.7. PESTLE Analysis
4.7.1. Political Factors
4.7.2. Economic Factors
4.7.3. Social Factors
4.7.4. Technological Factor
4.7.5. Legal Factors
4.7.6. Environmental Factors
4.8. Technological Roadmap
4.9. Regulatory Landscape by Region
4.9.1. North America
4.9.2. Europe
4.9.3. Asia Pacific
4.9.4. Middle East and Africa
4.9.5. South America
5. Emphysema Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
5.1. Emphysema Market Size and Forecast, by Type (2024-2032)
5.1.1. Centriacinar
5.1.2. Panacinar
5.1.3. Paraseptal
5.1.4. Others
5.2. Emphysema Market Size and Forecast, by Treatment (2024-2032)
5.2.1. Medication
5.2.2. Therapy
5.2.3. Surgery
5.2.4. Others
5.3. Emphysema Market Size and Forecast, by Distribution Channel (2024-2032)
5.3.1. Hospital Pharmacy
5.3.2. Online Pharmacy
5.3.3. Retail Pharmacy
5.4. Emphysema Market Size and Forecast, by Region (2024-2032)
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Middle East and Africa
5.4.5. South America
6. North America Emphysema Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
6.1. North America Emphysema Market Size and Forecast, by Type (2024-2032)
6.1.1. Centriacinar
6.1.2. Panacinar
6.1.3. Paraseptal
6.1.4. Others
6.2. North America Emphysema Market Size and Forecast, by Treatment (2024-2032)
6.2.1. Medication
6.2.2. Therapy
6.2.3. Surgery
6.2.4. Others
6.3. North America Emphysema Market Size and Forecast, by Distribution Channel (2024-2032)
6.3.1. Hospital Pharmacy
6.3.2. Online Pharmacy
6.3.3. Retail Pharmacy
6.4. North America Emphysema Market Size and Forecast, by Country (2024-2032)
6.4.1. United States
6.4.2. Canada
6.4.3. Mexico
7. Europe Emphysema Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
7.1. Europe Emphysema Market Size and Forecast, by Type (2024-2032)
7.2. Europe Emphysema Market Size and Forecast, by Treatment (2024-2032)
7.3. Europe Emphysema Market Size and Forecast, by Distribution Channel (2024-2032)
7.4. Europe Emphysema Market Size and Forecast, by Country (2024-2032)
7.4.1. United Kingdom
7.4.2. France
7.4.3. Germany
7.4.4. Italy
7.4.5. Spain
7.4.6. Sweden
7.4.7. Austria
7.4.8. Rest of Europe
8. Asia Pacific Emphysema Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
8.1. Asia Pacific Emphysema Market Size and Forecast, by Type (2024-2032)
8.2. Asia Pacific Emphysema Market Size and Forecast, by Treatment (2024-2032)
8.3. Asia Pacific Emphysema Market Size and Forecast, by Distribution Channel (2024-2032)
8.4. Asia Pacific Emphysema Market Size and Forecast, by Country (2024-2032)
8.4.1. China
8.4.2. S Korea
8.4.3. Japan
8.4.4. India
8.4.5. Australia
8.4.6. Indonesia
8.4.7. Malaysia
8.4.8. Vietnam
8.4.9. Taiwan
8.4.10. Rest of Asia Pacific
9. Middle East and Africa Emphysema Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
9.1. Middle East and Africa Emphysema Market Size and Forecast, by Type (2024-2032)
9.2. Middle East and Africa Emphysema Market Size and Forecast, by Treatment (2024-2032)
9.3. Middle East and Africa Emphysema Market Size and Forecast, by Distribution Channel (2024-2032)
9.4. Middle East and Africa Emphysema Market Size and Forecast, by Country (2024-2032)
9.4.1. South Africa
9.4.2. GCC
9.4.3. Nigeria
9.4.4. Rest of ME&A
10. South America Emphysema Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
10.1. South America Emphysema Market Size and Forecast, by Type (2024-2032)
10.2. South America Emphysema Market Size and Forecast, by Treatment (2024-2032)
10.3. South America Emphysema Market Size and Forecast, by Distribution Channel (2024-2032)
10.4. South America Emphysema Market Size and Forecast, by Country (2024-2032)
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest Of South America
11. Company Profile: Key Players
11.1. GlaxoSmithKline plc. (UK)
11.1.1. Company Overview
11.1.2. Business Portfolio
11.1.3. Financial Overview
11.1.3.1. Total Revenue
11.1.3.2. Segment Revenue
11.1.3.3. Regional Revenue
11.1.4. SWOT Analysis
11.1.5. Strategic Analysis
11.1.6. Recent Developments
11.2. F. Hoffmann-La Roche Ltd (Switzerland)
11.3. Novartis AG (Switzerland)
11.4. Eli Lilly and Company. (U.S.)
11.5. AstraZeneca (UK)
11.6. Pfizer Inc. (U.S.)
11.7. Takeda Pharmaceutical Company Limited. (Japan)
11.8. Bristol-Myers Squibb Company (U.S.)
11.9. Sanofi (France)
11.10. Bayer AG (Germany)
11.11. AbbVie Inc. (U.S.)
11.12. Allergan (Ireland)
11.13. Precigen (U.S.)
11.14. Pulmonx Corporation (U.S.)
11.15. Halozyme, Inc. (U.S.)
11.16. Mmariposa Health (U.S.)
11.17. Kamada Pharmaceuticals (Israel)
11.18. Olympus Corporation (Japan)
11.19. Spiration, Inc.(U.S.)
11.20. Lifetech Scientific (China)
11.21. XX Inc
12. Key Findings
13. Analyst Recommendations
13.1. Strategic Recommendations
13.2. Future Outlook
